ArQule, Inc. to Present at JMP Securities Annual Healthcare Conference

  ArQule, Inc. to Present at JMP Securities Annual Healthcare Conference

JMP Securities Healthcare Conference 2013

Business Wire

WOBURN, Mass. -- July 3, 2013

ArQule, Inc. (Nasdaq: ARQL) today announced that the Company will present at
the 8^th Annual JMP Securities Healthcare Conference on Wednesday, July 10,
2013 at 3:00 p.m. Eastern Time. The presentation will be web cast and may be
accessed through the investor relations section of the Company’s website,
http://www.arqule.com.

About ArQule

ArQule is a biotechnology company engaged in the research and development of
next-generation, small-molecule cancer therapeutics. The Company’s targeted,
broad-spectrum products and research programs are focused on key biological
processes that are central to human cancers. ArQule’s lead product, in Phase 2
and Phase 3 clinical development, is tivantinib (ARQ 197), an oral, selective
inhibitor of the MET receptor tyrosine kinase. The Company’s pipeline
includes: ARQ 092, designed to inhibit the AKT serine/threonine kinase: ARQ
087, designed to inhibit fibroblast growth factor receptor (FGFR); ARQ 621,
designed to inhibit the Eg5 kinesin motor protein; and ARQ 736, designed to
inhibit the RAF kinases. ArQule’s current discovery efforts, which are based
on the ArQule Kinase Inhibitor Platform (AKIP™), are focused on the
identification of novel kinase inhibitors that are potent, selective and do
not compete with ATP (adenosine triphosphate) for binding to the kinase.

Contact:

ArQule, Inc.
William B. Boni, 781-994-0300
VP, Investor Relations/
Corp. Communications
www.ArQule.com
 
Press spacebar to pause and continue. Press esc to stop.